Expand VNDA Menu
VNDA MENU

VNDA Latest Press Releases

-- January 8, 2026 --

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder PRNewswire 7:00 AM

-- December 30, 2025 --

Vanda Pharmaceuticals Announces FDA Approval of NEREUS (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness PRNewswire 6:13 PM

-- December 15, 2025 --

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis PRNewswire 7:00 AM

-- December 11, 2025 --

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PRNewswire 5:02 PM

-- December 4, 2025 --

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness PRNewswire 4:21 PM

-- November 28, 2025 --

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness PRNewswire 7:00 AM

-- November 17, 2025 --

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting PRNewswire 6:37 PM

-- November 5, 2025 --

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference PRNewswire 5:00 PM

-- October 29, 2025 --

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results PRNewswire 4:01 PM

-- October 22, 2025 --

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 PRNewswire 4:30 PM

-- October 8, 2025 --

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena PRNewswire 8:01 AM

-- October 1, 2025 --

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration PRNewswire 5:02 PM

-- September 25, 2025 --

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" PRNewswire 8:00 AM

-- August 28, 2025 --

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences PRNewswire 5:23 PM
Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera PRNewswire 7:00 AM

-- August 21, 2025 --

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz PRNewswire 4:40 PM

-- August 18, 2025 --

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder PRNewswire 7:00 AM
Market Data Delayed 15 Minutes